{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.16","upperLimit":"27.73","value":"21.5"},{"groupId":"OG001","lowerLimit":"17.89","upperLimit":"29.96","value":"23.5"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.76","upperLimit":"68.34","value":"61.7"},{"groupId":"OG001","lowerLimit":"51.74","upperLimit":"65.65","value":"58.8"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.71","upperLimit":"10.98","value":"6.7"},{"groupId":"OG001","lowerLimit":"3.44","upperLimit":"10.65","value":"6.4"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.32","upperLimit":"8.62","value":"4.8"},{"groupId":"OG001","lowerLimit":"3.44","upperLimit":"10.65","value":"6.4"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.30","upperLimit":"4.14","value":"1.4"},{"groupId":"OG001","lowerLimit":"0.01","upperLimit":"2.70","value":"0.5"}]}],"title":"Unable to evaluate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.67","upperLimit":"7.40","value":"3.8"},{"groupId":"OG001","lowerLimit":"2.04","upperLimit":"8.21","value":"4.4"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had at least one post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)","title":"Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}